3-Amino-3-Hydroxymethyl-Pyrrolidine-1-Carboxylic Acid Tert-Butyl Ester

Scale-up campaigns for macrocyclic HCV NS3/4A protease inhibitors routinely demand multi-hundred-kilogram deliveries of the (S)-configured 3-amino-3-hydroxymethylpyrrolidine-1-carboxylic acid tert-butyl ester as the chiral pool entry point. A production batch below 50 kg is executed in a glass-lined 630L reactor equipped with a retreat-curve impeller and a jacket capable of maintaining ±0.8 °C uniformity. The moisture-sensitive downstream coupling begins only after the content of free amine generated in situ by Boc deprotection is verified at ≥98.5 area% by HPLC (Column: Chiralpak AD-H, 250 × 4.6 mm, n-hexane/ethanol/diethylamine 80/20/0.1 v/v, 1.0 mL/min, 210 nm). For the pivotal amide bond formation linking the pyrrolidine amine to a quinoxalinecarboxylic acid fragment, the coupling cocktail employs HATU (1.05 eq.) and N,N-diisopropylethylamine (3.0 eq.) in anhydrous DMF (≤100 ppm H₂O by Karl Fischer). The acid is charged at −12 °C to suppress racemization; the reaction stream is then warmed to 0–2 °C over 4 h. Work-up quenches with 10 wt% citric acid solution, and the intermediate is crystallized from methyl tert-butyl ether/n-heptane (1/4 v/v) at a cooling rate of 5 °C/h to yield a product with a typical ee of 99.4%. Regulatory adherence follows ICH Q7 §7.3 for process validation, and the residual palladium level is monitored to remain below 10 µg/g per ICH Q3D Option 1. The isolated building block is further elaborated into the macrocyclic core of MK-5172 (grazoprevir)-type inhibitors, where the hydroxymethyl substituent participates in a late-stage intramolecular cyclization to lock the P2 moiety.

Process development for a benzylpiperidine-derived prolyl oligopeptidase (POP) inhibitor targeting the cognitive deficit pathway identified the Boc-protected amino alcohol as the only intermediate that retained crystallinity at ambient temperature, a property lost once the free amine is exposed. The synthetic sequence proceeds via activation of an indolylpropionic acid with 1,1′-carbonyldiimidazole (CDI, 1.08 eq.) in THF at 5–10 °C under a nitrogen blanket maintaining a dew point below −60 °C. After the imidazolide formation is confirmed by IR (disappearance of acid carbonyl at 1710 cm⁻¹), a pre-dried solution of the tert-butyl ester in THF (pre-dried over 4Å molecular sieves to ≤30 ppm water) is added in a single portion. An excess of moisture above 150 ppm in the combined reaction volume diverts CDI toward hydrolysis, dropping the coupling yield from 87% to below 42% and generating an intractable urea byproduct that co-elutes with the product on a C8 column (ACN/0.1% TFA gradient). The regulatory file for this advanced intermediate is structured under EMA guideline EMA/CHMP/QWP/245074/2015 for non-clinical quality, with a limit of ≤0.10% for the des-hydroxy analog specified by UPLC-UV (ACQUITY UPLC BEH Phenyl 1.7 µm, 2.1 × 100 mm). The final POP inhibitor, a 2-[(3-aminopyrrolidin-3-yl)methoxy]-5-fluorobenzonitrile congener disclosed in US 6,660,756, demonstrates sub-nanomolar IC₅₀ values and requires the (R)-enantiomer of the pyrrolidine scaffold to achieve the desired brain-to-plasma ratio of >3.2 in rodent models.

Introduction of a 7-[(3-amino-3-hydroxymethyl)pyrrolidin-1-yl] side chain onto the 1,8-naphthyridone or quinoline core of investigational 6-fluoroquinolones proceeds through a nucleophilic aromatic substitution that is kinetically competitive with hydroxide displacement at the 8-chloro position. A validated manufacturing procedure charges anhydrous DMSO (water <80 ppm) with the Boc-protected amino alcohol (1.15 eq. relative to the 7-chloro substrate), milled K₂CO₃ (2.2 eq., particle size D₉₀ ≤74 µm), and triethylbenzylammonium chloride (0.05 eq.) as a phase-transfer catalyst. The slurry is heated to 78 ± 2 °C for 16 h under an inert atmosphere. In-process control by UPLC (Acquity HSS T3, gradient from 95:5 water/ACN+0.1% formic acid to 5:95 in 8 min) tracks the disappearance of the chloro precursor; the target substitution achieves ≥96% conversion before chromatographic work-up. The crude is purified by silica gel chromatography (eluent DCM:MeOH 95:5) to remove the des-fluoro byproduct that forms at levels of 0.3–0.7% when the reaction temperature exceeds 82 °C. Residual solvent compliance for the isolated free base conforms to USP <467> Method A, with dimethyl sulfoxide limited to ≤5000 ppm. The final Boc cleavage with 4N HCl/dioxane at ambient temperature delivers the hydrochloride salt, which is directly processed to the 7-substituted fluoroquinolone carboxylic acid, exhibiting improved aqueous solubility (>8.2 mg/mL at pH 6.8) and a gram-positive MIC₉₀ of 0.03 µg/mL against Staphylococcus aureus ATCC 29213.

Generation of the free amino alcohol ligand from the tert-butyl ester precursor for asymmetric oxazaborolidine catalysis requires rigorous exclusion of adventitious aldehydes, which otherwise form imidazolidine adducts that poison the active catalyst. A multi-purpose 200L Hastelloy reactor charged with the Boc intermediate (18.5 kg, 1.0 eq.) in ethyl acetate (148 L) is treated with a 20 wt% solution of HCl in isopropanol (2.5 eq. of HCl) at 10 °C under nitrogen flow. After deprotection, the amino alcohol hydrochloride is isolated by filtration under a nitrogen blanket and immediately reslurried in anhydrous THF (100 L) with triethylamine (1.05 eq.) to liberate the free base. Without isolation, the slurry is filtered, and the filtrate is added dropwise to a 1.2 M solution of BH₃·THF complex (1.2 eq.) at −5 °C. The evolving hydrogen is vented through a flame arrestor, and the mixture is aged at 25 °C until ¹¹B NMR (128 MHz, C₆D₆) confirms complete coordination (signal shift from −0.8 to +18.3 ppm). The resulting (S)-configured oxazaborolidine catalyst precipitates upon addition of n-heptane and is stored as a 2.0 M stock solution in THF under argon. When deployed in the enantioselective reduction of acetophenone, the catalyst loading of 5 mol% with BH₃·Me₂S as stoichiometric reductant yields (R)-1-phenylethanol in 96% yield and 99.2% ee as determined by GC on a Lipodex E column (isothermal 110 °C). The process precludes exposure to atmospheric moisture above 45% RH; ambient humidity above this threshold triggers a rapid decline in catalyst turnover frequency from 12.4 to 3.7 h⁻¹ due to boroxine formation. Quality attributes for the catalyst precursor are specified in an internal monograph aligned with ASTM E2537-16 for reactor cleanliness, while the amino alcohol intermediate is controlled for both enantiomeric excess (HPLC, Chiralcel OD-H, >99.0%) and volatile organic impurities per ICH Q3C.

When a uridine-based antiviral phosphoramidate requires a pendant hydroxyl to conjugate the ProTide phosphate warhead, the dual functionality of the Boc-protected pyrrolidine amino alcohol eliminates the need for orthogonal protecting group manipulation at the ribose 5′-position. The synthesis begins by treating a 2′-methyluridine derivative with tert-butylmagnesium chloride (1.3 eq.) in THF at −20 °C, followed by addition of the protected amino alcohol (1.0 eq.) and N,N′-carbonyldiimidazole (1.15 eq.) to form the carbamate linkage at the pyrrolidine nitrogen. The hydroxymethyl group remains free and is subsequently phosphorylated with phenyl dichlorophosphate (1.05 eq.) and 2-ethylbutanol in the presence of 4.0 eq. of triethylamine at −78 to −65 °C. The process is monitored by ³¹P NMR (202 MHz, CD₃CN); appearance of a doublet at −3.2 ppm (J_P-H = 12.1 Hz) indicates complete phosphoramidation. The resulting prodrug intermediate is purified by flash chromatography (silica gel, gradient 0-5% MeOH in DCM) and deprotected with 30 vol% TFA in DCM at 0 °C to cleave the Boc group without degrading the phosphoramidate. Regulatory compliance for any subsequent GLP toxicology batch references FDA guidance for metabolites in safety testing (MIST), with the limit for the des-amino alcohol impurity set at ≤0.15% by HPLC/MS. The fully deprotected prodrug exhibits an intracellular triphosphate half-life exceeding 18 h in primary human hepatocytes, a critical parameter for once-daily dosing in HCV or respiratory syncytial virus (RSV) polymerase inhibition programs. Residual metal catalysts are controlled to ≤5 µg/g for palladium and ≤10 µg/g for copper using inductively coupled plasma mass spectrometry per USP <233>.